Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.

Journal of internal medicine - 1 Apr 2006

Zambon A, Brown B G, Hokanson J E, Motulsky A G, Brunzell J D

Abstract excerpt

OBJECTIVE: Lipid-lowering therapy (LL-Rx) reduces coronary artery disease (CAD) but the response varies amongst individuals. We investigated the contribution of three genetic forms of dyslipidaemia characterized by elevated plasma apo B, familial hypercholesterolaemia (FH), familial combined hyperlipidaemia (FCHL), and elevated Lp(a), to the angiographic response with LL-Rx. METHODS AND RESULTS: Fifty-one men,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coronary Angiography
Share to Coronary Stenosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Hypercholesterolemia

Share to Hypolipidemic Agents

Share to Lipoproteins, LDL

Share to Lovastatin

Share to Niacin

Source

Identifiers

PMID: 16594908
DOI: 10.1111/j.1365-2796.2006.01626.x

Genes

CAD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.PMID 16594908Read ↗

Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.Semantic proximity Read ↗

Nutritional, metabolic, and genetic determinants of the progression of coronary heart disease. STARS Group.Semantic proximity Read ↗

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.Semantic proximity Read ↗

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.Semantic proximity Read ↗

Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.Semantic proximity Read ↗

Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.Semantic proximity Read ↗

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA).Semantic proximity Read ↗

Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.